ZGN-1061

ZGN-1061
Names
	Preferred IUPAC name [(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] 3-(2-morpholin-4-ylethyl)azetidine-1-carboxylate
	Other names ZGN-1061, Aclimostat
Identifiers
CAS Number	2082752-83-6;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL4297651;
ChemSpider	81368488;
DrugBank	DB16079;
PubChem CID	126573394;
UNII	X150A3JK8R;
	InChI InChI=1S/C26H42N2O6/c1-18(2)5-6-21-25(3,34-21)23-22(30-4)20(7-9-26(23)17-32-26)33-24(29)28-15-19(16-28)8-10-27-11-13-31-14-12-27/h5,19-23H,6-17H2,1-4H3/t20-,21-,22-,23-,25+,26+/m1/s1 Key: QJWJPMLDQYEPPW-AUKZVGPFSA-N;
	SMILES CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)N4CC(C4)CCN5CCOCC5)OC)C;
Properties
Chemical formula	C26H42N2O6
Molar mass	478.630 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

ZGN-1061 is an experimental drug that was developed by Zafgen for treatment of obesity and type 2 diabetes. It has a similar mechanism of action as the discontinued drug Beloranib but was considered safer; however, its development was also halted because of safety concerns.^[1]^[2]^[3]

References

↑ Christoffersen, Berit Østergaard; Sanchez‐Delgado, Guillermo; John, Linu Mary; Ryan, Donna H.; Raun, Kirsten; Ravussin, Eric (April 2022). "Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss". Obesity. 30 (4): 841–857. doi:10.1002/oby.23374. ISSN 1930-7381. PMC 9310705.
↑ Wentworth, John M.; Colman, Peter G. (July 2020). "The methionine aminopeptidase 2 inhibitor ZGN‐1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo‐controlled trial". Diabetes, Obesity and Metabolism. 22 (7): 1215–1219. doi:10.1111/dom.14009. hdl:11343/275507.
↑ Goya Grocin, Andrea; Kallemeijn, Wouter W.; Tate, Edward W. (October 2021). "Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity". Trends in Pharmacological Sciences. 42 (10): 870–882. doi:10.1016/j.tips.2021.07.004. hdl:10044/1/102175.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Christoffersen, Berit Østergaard; Sanchez‐Delgado, Guillermo; John, Linu Mary; Ryan, Donna H.; Raun, Kirsten; Ravussin, Eric (April 2022). "Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss". Obesity. 30 (4): 841–857. doi:10.1002/oby.23374. ISSN 1930-7381. PMC 9310705.

[2] Wentworth, John M.; Colman, Peter G. (July 2020). "The methionine aminopeptidase 2 inhibitor ZGN‐1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo‐controlled trial". Diabetes, Obesity and Metabolism. 22 (7): 1215–1219. doi:10.1111/dom.14009. hdl:11343/275507.

[3] Goya Grocin, Andrea; Kallemeijn, Wouter W.; Tate, Edward W. (October 2021). "Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity". Trends in Pharmacological Sciences. 42 (10): 870–882. doi:10.1016/j.tips.2021.07.004. hdl:10044/1/102175.

[1]

[2]

[3]